Jobs
-
Tiziana Life Sciences has announced that a Phase 1 clinical trial of its intranasal Foralumab human anti-CD3 monoclonal antibody was well tolerated at doses of 10, 50 and 250 µg per day and demonstrated “significant… Read more . . .
-
Milestone Pharmaceuticals has announced the appointment of former Sanofi executive Amit Hasija as Chief Financial Officer and Executive VP of Corporate Development. Milestone’s etripamil, an intranasal calcium channel antagonist, is in Phase 3 development for the treatment… Read more . . .
-
CDMO Experic has announced the appointment of Denise Sabaday as vice president of business development. Sabaday was most recently Executive VP of Business Development and Marketing at Transformative Pharmaceutical Solutions and was previously Director of Business… Read more . . .
-
Theravance Biopharma has announced positive results from a Phase 1 single-ascending dose and multiple-ascending dose trial of its TD-8236 pan-JAK inhibitor DPI for the treatment of inflammatory lung diseases. The company had announced initiation of… Read more . . .
-
Janssen Pharmaceutical Companies has announced that both the ASPIRE I & ASPIRE II Phase 3 clinical studies of esketamine nasal spray in addition to standard of care (SOC) for the treatment of major depressive disorder… Read more . . .
-
Handheld nebulizer manufacturer HCmed Innovations announced that it has accepted an invitation to build an R&D center and production facility in the newly opened Wuxi International Life Science Innovation Park, which is anchored by AstraZeneca.… Read more . . .
-
Hovione Technology has partnered with Kiel University Institute of Pharmacy on methods of dry powder formulation for delivery of high doses of antibiotics using Hovione Technology TwinMax and 8Shot DPIs, the company said. Areas of… Read more . . .
-
LBB Specialties announced that it has signed a strategic partnership deal with Meggle for distribution of Meggle’s pharmaceutical lactose excipients, including lactose for inhalation formulations, in the United States through LBB’s Charkit Chemical and American… Read more . . .
-
AstraZeneca said that the 52-week Phase 3 ETHOS trial of its Breztri Aerosphere (formerly PT010) budesonide/glycopyrronium/formoterol fumarate MDI in more than 8,500 patients with moderate to very severe COPD and a history of exacerbations within the… Read more . . .
-
The FDA has approved Akorn’s ANDA for its azelastine hydrochloride nasal spray, 0.15%, for the treatment of allergic and perennial rhinitis in patients 6 years old and older, the company said. In May 2019, the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK